|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:alternativeName
|
gptkb:Rimonabant
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:ATCCode
|
gptkb:A08AX01
|
|
gptkbp:CASNumber
|
gptkb:168273-06-1
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:drugClass
|
anorectic
cannabinoid receptor antagonist
|
|
gptkbp:hasMolecularFormula
|
gptkb:C22H21Cl3N4O
|
|
gptkbp:hasReasonForWithdrawal
|
psychiatric side effects
|
|
gptkbp:hasSMILES
|
CC1=NN(C(=C1C2=CC=CC=C2Cl)C3=CC(=C(C=C3)Cl)Cl)C(=O)N4CCCCC4
|
|
gptkbp:hasTherapeuticUse
|
anti-obesity agent
smoking cessation aid
|
|
gptkbp:hasUNII
|
N9YNS0M02X
|
|
gptkbp:hasYearOfWithdrawal
|
2008
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR141716A
|
|
gptkbp:isNotApprovedIn
|
gptkb:United_States
|
|
gptkbp:IUPACName
|
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
CB1 receptor antagonist
|
|
gptkbp:molecularWeight
|
463.8 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL37541
gptkb:DB06155
104850
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
suicidal ideation
|
|
gptkbp:target
|
gptkb:cannabinoid_receptor_type_1_(CB1)
|
|
gptkbp:wasMarketedIn
|
gptkb:Europe
|
|
gptkbp:wasWithdrawnFromMarket
|
true
|
|
gptkbp:bfsParent
|
gptkb:CB1
|
|
gptkbp:bfsLayer
|
6
|